Obesity-associated cardiometabolic complications in polycystic ovary syndrome: The potential role of sodium-glucose cotransporter-2 inhibitors.
Obesity-associated cardiometabolic complications in polycystic ovary syndrome: The potential role of sodium-glucose cotransporter-2 inhibitors.
复制标题
DOI：
10.3389/fendo.2023.951099
复制
发表时间：
2023
影响因子：
5.2
通讯作者：
中科院分区：
文献类型：
--
作者：
多囊卵巢综合征（PCOS）是育龄妇女最常见的内分泌疾病。PCOS的特征是雄激素过多、少排卵/无排卵和卵巢的多囊外观。多囊卵巢综合征的妇女有多种心血管危险因素的患病率增加，如胰岛素抵抗、高血压、肾损伤和肥胖。不幸的是，缺乏有效的，循证的药物治疗，以针对这些心脏代谢并发症。钠-葡萄糖协同转运蛋白-2（SGLT 2）抑制剂可为伴或不伴2型糖尿病的患者提供心血管保护。尽管SGLT 2抑制剂如何提供心血管保护的确切机制尚不清楚，但这种保护的许多机制假设包括调节肾素-血管紧张素系统和/或交感神经系统以及改善线粒体功能。最近的临床试验和基础研究数据显示，SGLT 2抑制剂在治疗PCOS肥胖相关心脏代谢并发症中具有潜在作用。该叙述性综述讨论了SGLT 2抑制剂在PCOS心脏代谢疾病中的有益作用机制。
Polycystic Ovary Syndrome (PCOS) is the most common endocrine disorder in reproductive-age women. PCOS is characterized by androgen excess, oligo/anovulation, and polycystic appearance of the ovaries. Women with PCOS have an increased prevalence of multiple cardiovascular risk factors such as insulin resistance, hypertension, renal injury, and obesity. Unfortunately, there is a lack of effective, evidence-based pharmacotherapeutics to target these cardiometabolic complications. Sodium-glucose cotransporter-2 (SGLT2) inhibitors provide cardiovascular protection in patients with and without type 2 diabetes mellitus. Although the exact mechanisms of how SGLT2 inhibitors confer cardiovascular protection remains unclear, numerous mechanistic hypotheses for this protection include modulation of the renin-angiotensin system and/or the sympathetic nervous system and improvement in mitochondrial function. Data from recent clinical trials and basic research show a potential role for SGLT2 inhibitors in treating obesity-associated cardiometabolic complications in PCOS. This narrative review discusses the mechanisms of the beneficial effect of SGLT2 inhibitors in cardiometabolic diseases in PCOS.